Home

A new approach to
calcification disorders

Home

SANIFIT

Sanifit is a biopharmaceutical company focused on treatments for calcification disorders, with SNF472 as lead compound. The company was founded in 2007 as a spin-off from the University of the Balearic Islands, and has offices in Palma (Spain) and San Diego (USA). SNF472 is an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease population undergoing haemodialysis.

Sanifit has completed phase Ia studies with healthy volunteers and a phase Ib/IIa study with haemodialysis patients. After a series C funding round of $41.3M (€36.6M), Sanifit will start a phase IIb study in ESRD and extend the orphan program in calciphylaxis into phase II/III clinical trials.

ABOUT US

PROJECT SUPPORTED BY

OVERVIEW PIPELINE

THERAPEUTIC PIPELINE

OTC PIPELINE

LATEST NEWS

  • Sanifit appoints Preston S. Klassen MD, MHS as Chief Medical Officer and announces new US subsidiary

    Former Head of R&D at Orexigen Therapeutics and Therapeutic Area Head for Nephrology at Amgen appointed as CMO CMO appointment and launch of US subsidiary are significant steps in establishing a US presence Palma de Mallorca, Spain, 07 June 2016 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today […]

  • Sanifit Expands Board with Senior Hire

    Keith R. Leonard, Former President & CEO of Kythera Biopharmaceuticals Appointed to Sanifit’s Board of Directors Palma de Mallorca, Spain, May 10, 2016 – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announces the appointment of Keith R. Leonard to the Board of Directors. Mr Leonard brings over 20 […]

  • Sanifit announces the creation of a Steering Committee for its Phase 2b ESRD Clinical Program with SNF472

    Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, announced today the creation of a Steering Committee for its phase 2b clinical trial in End-Stage Renal Disease with SNF472. SNF472 is being developed by Sanifit for the treatment of cardiovascular diseases linked to calcification in ESRD patients on dialysis. This patient population experiences significantly higher rates of […]

  • Sanifit and Mitelos make available to Doctors and patients a new alternative in osteoporosis

    Sanifit and Mitelos have successfully concluded the development, registration and industrial scaled up of SNF671, a breakthrough patent protected dietary supplement to prevent osteoporosis within postmenopausal women, which was originated at the Laboratory of Renal Lithiasis Research of the University of the Balearic Islands. SNF671 has proven efficacy both in in vitro and in vivo […]

  • Presentation of SNF472 Data at the American Society of Nephrology Kidney Week 2015

    Sanifit Announces Presentation of SNF472 Data at the American Society of Nephrology Kidney Week 2015

Your name (required)

Phone (required)

Company

E-mail (required)

Comments

CONTACT

Sanifit

SPAIN
ParcBIT – Ctra Valldemossa km7.4
Building Europa, 2nd floor
07121 Palma

 +34 971 439 925

 info@sanifit.com



USA
4660 La Jolla Village Drive
Suite #500
San Diego, CA 92122